9-amino-l,2,3,4-tetrahydroacridin-l-ols: Synthesis and Evaluation As Potential Alzheimer'S Disease Therapeutics

Gregory M. Shutske, Frank A. Pierrat, Kevin J. Kapples, Michael L. Cornfeldt, Mark R. Szewczak, Francis P. Huger, Gina M. Bores, Vahram Haroutunian, Kenneth L. Davis

Research output: Contribution to journalArticlepeer-review

108 Scopus citations

Abstract

The synthesis of a series of 9-amino-l,2,3,4-tetrahydroacridin-l-ols is reported. These compounds are related to l,2,3,4-tetrahydro-9-acridinamine (THA, tacrine). They inhibit acetylcholinesterase in vitro and are active in a model that may be predictive of activity in Alzheimer's disease—the scopolamine-induced impairment of 24-h memory of a passive dark-avoidance paradigm in mice. Two compounds, (±)-9-amino-l,2,3,4-tetrahydroacridin-l-ol maleate (la, HP-029) and (±)-9-(benzylamino)-l,2,3,4-tetrahydroacridin-l-ol maleate (1p, HP-128), were also active in reversing the deficit in 72-h retention of a one-trial dark-avoidance task in rats, induced by ibotenic acid lesions in the nucleus basalis magnocellularis. In addition, compound lp showed potent in vitro inhibition of the uptake of radiolabeled noradrenaline and dopamine (IC50 = 0.070 and 0.30 μM, respectively). Compounds la and lp, which showed less acute toxicity in both rats and mice than THA, are in phase II and phase I clinical trials, respectively, for Alzheimer's disease.

Original languageEnglish
Pages (from-to)1805-1813
Number of pages9
JournalJournal of Medicinal Chemistry
Volume32
Issue number8
DOIs
StatePublished - 1 Aug 1989
Externally publishedYes

Fingerprint

Dive into the research topics of '9-amino-l,2,3,4-tetrahydroacridin-l-ols: Synthesis and Evaluation As Potential Alzheimer'S Disease Therapeutics'. Together they form a unique fingerprint.

Cite this